Morning Briefing
Summaries of health policy coverage from major news organizations
Small Clinical Trial Examines Drug's Ability To Reduce HIV In Body
In the first human trial of GlaxoSmithKline's (GSK) experimental HIV drug S/GSK1349572, the drug was able to reduce HIV to undetectable levels in 70 percent of the 35 patients taking the treatment for 10 days, according to findings presented at the International AIDS Society's conference in Cape Town, South Africa, Bloomberg reports.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
